Do Boston Scientific’s (BSX) WATCHMAN Win and Asurys Launch Quietly Recast Its Long-Term Growth Story?

Simply Wall St.04-03

In late March 2026, Boston Scientific announced landmark CHAMPION-AF trial results showing its WATCHMAN FLX left atrial appendage closure device matched non-vitamin K antagonist oral anticoagulants on...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624684241?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","is_english":true,"pubTime":"2026-04-03 02:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624684241","market":"hk","top_or_hot":-1,"title":"Do Boston Scientific’s (BSX) WATCHMAN Win and Asurys Launch Quietly Recast Its Long-Term Growth Story?","media":"Simply Wall St.","content":"<div>\n<p>In late March 2026, Boston Scientific announced landmark CHAMPION-AF trial results showing its WATCHMAN FLX left atrial appendage closure device matched non-vitamin K antagonist oral anticoagulants on...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/do-boston-scientifics-bsx-watchman-win-and-asurys-launch-qui\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Do Boston Scientific’s (BSX) WATCHMAN Win and Asurys Launch Quietly Recast Its Long-Term Growth Story?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDo Boston Scientific’s (BSX) WATCHMAN Win and Asurys Launch Quietly Recast Its Long-Term Growth Story?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-03 02:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/do-boston-scientifics-bsx-watchman-win-and-asurys-launch-qui><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late March 2026, Boston Scientific announced landmark CHAMPION-AF trial results showing its WATCHMAN FLX left atrial appendage closure device matched non-vitamin K antagonist oral anticoagulants on...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/do-boston-scientifics-bsx-watchman-win-and-asurys-launch-qui\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFTCPJ56.SGD","symbol_name":"Janus Henderson Global Life Sciences A Acc SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/do-boston-scientifics-bsx-watchman-win-and-asurys-launch-qui","article_id":"2624684241","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/do-boston-scientifics-bsx-watchman-win-and-asurys-launch-qui","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624684241","pubTimestamp":1775155143,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late March 2026, Boston Scientific announced landmark CHAMPION-AF trial results showing its WATCHMAN FLX left atrial appendage closure device matched non-vitamin K antagonist oral anticoagulants on stroke prevention while reducing clinically relevant bleeding, alongside FDA 510(k) clearance for the Asurys Fluid Management System for endoscopic urologic procedures.\nThe unusual combination of clinically strong WATCHMAN data and a new kidney-stone-focused irrigation platform with intrarenal...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","BK4588":"碎股","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0138981039.USD":"FIDELITY FUNDS SUSTAINABLE MULTI ASSET INCOME \"A\" INC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4581":"高盛持仓","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","BSX":"波士顿科学","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","BSX.AU":"BLACKSTONE MINERALS LTD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4082":"医疗保健设备","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"translate_title":"Boston Scientific(BSX)的WATCHMAN Win和Asurys的推出是否悄然重塑了其长期增长故事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1.5,"BSX.AU":1.5},"content_text":"In late March 2026, Boston Scientific announced landmark CHAMPION-AF trial results showing its WATCHMAN FLX left atrial appendage closure device matched non-vitamin K antagonist oral anticoagulants on stroke prevention while reducing clinically relevant bleeding, alongside FDA 510(k) clearance for the Asurys Fluid Management System for endoscopic urologic procedures. The unusual combination of clinically strong WATCHMAN data and a new kidney-stone-focused irrigation platform with intrarenal pressure management arrives just as analysts question the durability of Boston Scientific’s electrophysiology and Watchman growth engines. We’ll now examine how the CHAMPION-AF WATCHMAN results could influence Boston Scientific’s investment narrative, especially around growth sustainability and risk. We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementBoston Scientific Investment Narrative RecapTo own Boston Scientific today, you need to believe it can keep translating specialty cardiology and urology innovation into durable procedure volume and pricing, despite recent competitive and legal headwinds. The CHAMPION-AF WATCHMAN data strengthen the clinical backbone of one of its key growth engines, but the stock’s sharp pullback and a new securities class action keep the near term centered on sentiment risk rather than a clear, single upside catalyst. Among the recent announcements, the CHAMPION-AF trial results stand out because they go directly to the heart of the current debate: can WATCHMAN support Boston Scientific’s growth ambitions if electrophysiology momentum softens. By showing non-inferior stroke prevention versus NOACs with lower clinically relevant bleeding, the data could reinforce confidence in left atrial appendage closure as a long-term pillar, even as reimbursement and competition remain active swing factors. Yet, behind the positive trial headlines, investors also need to weigh the emerging class action and what it could imply for... Read the full narrative on Boston Scientific (it's free!)Boston Scientific’s narrative projects $27.0 billion revenue and $5.2 billion earnings by 2029.Uncover how Boston Scientific's forecasts yield a $102.00 fair value, a 65% upside to its current price.Exploring Other PerspectivesBSX 1-Year Stock Price Chart Six members of the Simply Wall St Community currently see Boston Scientific’s fair value between US$87 and US$102, highlighting a wide band of conviction. Against that backdrop, the dependence on continued WATCHMAN and electrophysiology adoption after CHAMPION-AF is a key issue that could shape how those expectations eventually line up with business performance.Explore 6 other fair value estimates on Boston Scientific - why the stock might be worth just $87.28!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.Looking For Alternative Opportunities?Every day counts. These free picks are already gaining attention. See them before the crowd does:This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.Find 63 companies with promising cash flow potential yet trading below their fair value.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Boston Scientific might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624684241","isCrawlerRequest":true}